Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as HCW9302, an IL-2 fusion protein
HCW9302 · 1 trial · 1 indication
Evaluate the safety profile of HCW9302 monotherapy in subjects with Alopecia Areata (AA), based on the incidence, type, and severity of adverse events (AEs) classified according to MedDRA.
| Arm | Type | Description |
|---|---|---|
| Study of HCW9302, an IL-2 fusion protein, for alopecia areata | EXPERIMENTAL | Single dose subcutaneous injection of HCW9302. |
| Name | Type | Description |
|---|---|---|
| HCW9302, an IL-2 fusion protein | DRUG | Injection |
Inclusion Criteria: 1. Adult women who are 18 to 70 years of age, or adult males who are 18 to 60 years of age at the time of informed consent. 2. Clinical diagnosis of Alopecia Areata (AA) (including ophiasis, totalis or universalis forms) at Screening. 3. Negative serum pregnancy test within 14 d...
HCW9302 is an investigational interleukin-2 (IL-2) fusion protein being developed by HCW Biologics Inc. for the treatment of alopecia areata, an autoimmune condition that causes hair loss. It is currently in Phase 1 clinical development and has not been approved by the FDA.
HCW9302 is being studied as a treatment for alopecia areata (AA), an autoimmune skin condition that causes hair loss. The Phase 1 trial is enrolling adults 18 years and older with alopecia areata in the United States. It is investigational and has not been approved for any indication.
HCW9302 targets interleukin-2, or IL-2. It is an IL-2 fusion protein designed to engage the IL-2 pathway, which plays a role in regulating immune cell activity relevant to autoimmune conditions such as alopecia areata. The drug is in Phase 1 development.
HCW9302 is developed by HCW Biologics Inc., which trades on the Nasdaq under the ticker HCWB. The company is sponsoring the Phase 1 clinical trial of the IL-2 fusion protein in alopecia areata.
HCW9302 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The single Phase 1 trial is currently recruiting participants with alopecia areata, with a planned enrollment of 30 patients.
HCW9302 is being evaluated in one Phase 1 clinical trial, NCT07049328, titled "HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata." The trial is recruiting 30 participants aged 18 years and older in the United States. It is an uncontrolled, non-randomized study.
Yes. HCW9302 is also referred to as an IL-2 fusion protein, reflecting its structure as a fusion protein that targets interleukin-2. Searches for either name refer to the same investigational asset developed by HCW Biologics Inc. for alopecia areata.